Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Alpha-1 antitrypsin (AAT) deficiency is well-suited as a target for human gene transfer. We performed a phase 1, open-label, dose-escalation clinical trial of a recombinant adeno-associated virus (rAAV) vector expressing normal (M) AAT packaged into serotype 1 AAV capsids delivered by i.m. injection. Nine AAT-deficient subjects were enrolled sequentially in cohorts of 3 each at doses of 6.9 × 10 12 , 2.2 × 10 13 , and 6.0 × 10 13 vector genome particles per patient. Four subjects receiving AAT protein augmentation discontinued therapy 28 or 56 days before vector administration. Vector administration was well tolerated, with only mild local reactions and 1 unrelated serious adverse event (bacterial epididymitis). There were no changes in hematology or clinical chemistry parameters. M-specific AAT was expressed above background in all subjects in cohorts 2 and 3 and was sustained at levels 0.1% of normal for at least 1 year in the highest dosage level cohort, despite development of neutralizing antibody and IFN-γ enzyme-linked immunospot responses to AAV1 capsid at day 14 in all subjects. These findings suggest that immune responses to AAV capsid that develop after i.m. injection of a serotype 1 rAAV vector expressing AAT do not completely eliminate transduced cells in this context.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, other trials have observed T-cell immune responses that did not clear transgene expression, particularly muscle-directed trials [86, 90, 91].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [90]
In the citing paper
“Despite the observation of immune responses after intravenous (i.v.) administration of AAV, concurrent clinical trials using intramuscular (i.m.) delivery of AAV revealed long-term transgene expression without immune suppression, regardless of significant immune cell infiltration.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [7]
In the citing paper
“whereas muscle-directed AAV gene therapy clinical trials have shown long-lived transgene expression and induction of Tregs.7,8,11,51”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [7]
In the citing paper
“have been implicated in contributing to long-term transgene expression in preclinical studies (35, 160, 161) and clinical trials (162 -164).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [162]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“This complexity also comes into play when comparing our data with that in the rAAV2–factor IX clinical trial (14).”
BackgroundResultHIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Betts, M. R. (2006) · Blood · doi:10.1182/blood-2005-12-4818 · Cited by 1,826
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 3×
“33, which is unexpected on the basis of animal immunization studies that indicate few shared B cell epitopes between these AAVs (18, 19).”
BackgroundInfluentialSelf-citationWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“Consistent with previously published results (16), antibodies to AAV7 and AAV8 were detected at baseline infrequently (in 2 of 9 subjects, both of whom had received the rAAV2 vector in a previous study) and antibodies to AAVrh32.”
ResultSelf-citationNovel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 696 · cited 1×
“other Ad helper genes and the AAV1 rep and cap genes (23).”
BackgroundKessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Self-citationProduction and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Self-citationAdeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323 · cited 3×
“33, which is unexpected on the basis of animal immunization studies that indicate few shared B cell epitopes between these AAVs (18, 19).”
BackgroundInfluentialSelf-citationSong, S., Morgan, M., Ellis, T., Poirier, A., Chesnut, K., Wang, J., Brantly, M., Muzyczka, N., Byrne, B. J., Atkinson, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14384 · Cited by 304 · cited 1×
“Because of a marked efficiency advantage for vectors packaged in AAV serotype 1 capsid and injected in murine muscle, our group proceeded with preclinical development of a cross-packaged or pseudotyped rAAV–AAT vector, using the same rAAV–AAT gene cassette as in the previous clinical trial but packaged in a serotype 1…”
MethodSelf-citationThe Alpha1-antitrypsin Gene and Its Mutations
Crystal, R. G., Brantly, M. L., Hubbard, R. C., Curiel, D. T., States, D. J., & Holmes, M. D. (1989) · Chest · doi:10.1378/chest.95.1.196 · Cited by 209
Self-citation
Research works printed but not linked: 2
- 10.1016/s0002-9343(88)80069-x · doi:10.1016/s0002-9343(88)80069-x
- A Poirier, et al., Toxicology and biodistribution studies of a recombinant adeno-associated virus 2-α1-antitrypsin vector. Preclinica 2, 43–51 (2004).
Cited by
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“19 17, 18, 57-60 Thus, although antibodies to AAV2 are clearly the most prevalent in humans (up to 70%), the natural host for this serotype, antibodies recognizing virtually all AAV serotypes can be found in a large proportion of individuals.”
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Self-citationState-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“AAV1 vector administration was associated with the development of anti-capsid T cell responses in all evaluated subjects.(202) Flotte et al.”
BackgroundProgress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
AAV-Mediated Gene Therapy for Research and Therapeutic Purposes
Samulski, R. J., & Muzyczka, N. (2014) · Annual Review of Virology · doi:10.1146/annurev-virology-031413-085355 · Cited by 551
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
A Review of α 1 -Antitrypsin Deficiency
Stoller, J. K., & Aboussouan, L. S. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1428ci · Cited by 413
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Bevan, A. K., Duque, S., Foust, K. D., Morales, P. R., Braun, L., Schmelzer, L., Chan, C. M., McCrate, M., Chicoine, L. G., Coley, B. D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.157 · Cited by 337
Flotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
“The rAAV1-CB-hAAT vector was identical to the vector used in a phase 1 clinical trial (Brantly et al. , 2009) except that it was made using a recombinant HSV complementation system in suspension baby hamster kidney (BHK) cells (Kang et al. , 2009; Thomas et al. , 2009), based on the method of…”
InfluentialSelf-citationRapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale
Lock, M., Alvira, M., Vandenberghe, L. H., Samanta, A., Toelen, J., Debyser, Z., & Wilson, J. M. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.055 · Cited by 334
“Most early AAV gene therapy studies were performed with serotype 2 vectors, but vector systems based on other AAV serotypes with more efficient gene delivery and different tissue specificity are currently in human trials and their use will likely increase (Brantly et al. , 2009; Neinhuis, 2009).”
Self-citationGreene, C. M., Marciniak, S. J., Teckman, J., Ferrarotti, I., Brantly, M. L., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 324
Self-citationKeeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Self-citationIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
“Unlike rabbit vaccination experiments as in Figure 5A, human PEI is highly cross-reactive across many serotypes, making it difficult for any AAV-like particle escape this wide breadth PEI in humans (Brantly et al., 2009; Calcedo et al., 2009).”
BackgroundManufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
Microvesicle-associated AAV Vector as a Novel Gene Delivery System
Maguire, C. A., Balaj, L., Sivaraman, S., Crommentuijn, M. H., Ericsson, M., Mincheva-Nilsson, L., Baranov, V., Gianni, D., Tannous, B. A., Sena-Esteves, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.303 · Cited by 283
Serine proteases of the human immune system in health and disease
Heutinck, K. M., ten Berge, I. J. M., Hack, C. E., Hamann, J., & Rowshani, A. T. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.04.020 · Cited by 262
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
Self-citationHumoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243
Self-citationBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Role of alpha‐1 antitrypsin in human health and disease
de Serres, F., & Blanco, I. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12239 · Cited by 240
Unraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene Transfer
Pulicherla, N., Shen, S., Yadav, S., Debbink, K., Govindasamy, L., Agbandje-McKenna, M., & Asokan, A. (2011) · Molecular Therapy · doi:10.1038/mt.2011.22 · Cited by 224
Structural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219
Self-citationWeleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., Jensen, L., McBride, M. T., Flotte, T. R., Humphries, M., Calcedo, R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.003 · Cited by 218
Self-citationWang, L., Calcedo, R., Bell, P., Lin, J., Grant, R. L., Siegel, D. L., & Wilson, J. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.031 · Cited by 212
“However, the breadth of the humoral response seen in primates after nat-ural infections contrasts with the narrow serotype-specific response elicited in nonprimate animal models after exposure to AAV vectors (Brantly et al. , 2009).”
Self-citationMingozzi, F., & High, K. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041936 · Cited by 206
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 187
“In another approach, a phase I trial on patients with alpha ‐ 1 ‐ antitrypsin (AAT) deficiency was conducted with AAV vectors expressing the human AAT gene [166].”
Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
Arjomandnejad, M., Kopec, A. L., & Keeler, A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020287 · Cited by 171
Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70314 · Cited by 169
“injection, which has persisted in individuals despite the emergence of anti-capsid effector T cells (which have included both CD4+ and CD8+ cells, with CD8+ population cells having markers consistent with cytotoxic T cells) (13, 14).”
BackgroundMethodSelf-citationCarpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165
Qiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X. (2011) · Gene Therapy · doi:10.1038/gt.2010.157 · Cited by 163
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“In contrast, other trials have observed T-cell immune responses that did not clear transgene expression, particularly muscle-directed trials [86, 90, 91].”
ResultSelf-citationSmith, B. K., Collins, S. W., Conlon, T. J., Mah, C. S., Lawson, L. A., Martin, A. D., Fuller, D. D., Cleaver, B. D., Clément, N., Phillips, D., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.250 · Cited by 158
“These immune responses have been reported previously during other gene therapy clinical trials or ERT-related studies and did not result in serious adverse events (Kishnani et al., 2007; Brantly et al., 2009; Ponder, 2011).”
ResultSelf-citationTseng, Y.-S., & Agbandje-McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 134
Parvovirus glycan interactions
Huang, L.-Y., Halder, S., & Agbandje-McKenna, M. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.05.007 · Cited by 136
“Due to their ability to package and delivery foreign genes to different tissue types and the lack of associated disease, AAVs are being developed and used as gene delivery vectors, and serve as the first approved gene therapy treatment [34-40].”
BackgroundMicrodystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy
Shin, J.-H., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L., & Duan, D. (2013) · Molecular Therapy · doi:10.1038/mt.2012.283 · Cited by 133
Pastore, N., Blomenkamp, K., Annunziata, F., Piccolo, P., Mithbaokar, P., Maria Sepe, R., Vetrini, F., Palmer, D., Ng, P., Polishchuk, E., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202046 · Cited by 142
“…lung disease due to AAT deficiency can be prevented by protein augmentation therapy (American Thoracic/European Respiratory Society, 2003; Wewers et al, 1987) or replenishment of the deficient gene product via AAV-mediated muscle-directed gene therapy (Brantly et al, 2009; Flotte et al, 2004).”
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140
Self-citationMingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
Ferreira, V., Twisk, J., Kwikkers, K., Aronica, E., Brisson, D., Methot, J., Petry, H., & Gaudet, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.169 · Cited by 137
“Cellular immune responses were also noted in other clinical studies in which rAAV vectors were administered locally, by IM injection (Brantly et al. , 2009; Flotte et al. , 2011).”
InfluentialCharacterization of a recombinant adeno-associated virus type 2 Reference Standard Material
Lock, M., McGorray, S., Auricchio, A., Ayuso, E., Beecham, E. J., Blouin-Tavel, V., Bosch, F., Bose, M., Byrne, B. J., Caton, T., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.223 · Cited by 131
“Most of the historic data involve rAAV serotype 2 vectors, but vector systems based on other AAV serotypes with more efficient gene delivery profiles in specific tissues are currently in human trials (Brantly et al. , 2009; Nienhuis, 2009) and their use will likely increase.”
Self-citationPriddy, F. H., Lewis, D. J. M., Gelderblom, H. C., Hassanin, H., Streatfield, C., LaBranche, C., Hare, J., Cox, J. H., Dally, L., Bendel, D., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30003-7 · Cited by 131
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
Therapeutic approaches to muscular dystrophy
Goyenvalle, A., Seto, J. T., Davies, K. E., & Chamberlain, J. S. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr105 · Cited by 130
“Capsid-specific T-cell responses are also sometimes primed by the delivery of the rAAV vector to muscle (36,56), but this does not necessarily cause loss of transgene expression (56).”
BackgroundGreenberg, B., Butler, J., Felker, G. M., Ponikowski, P., Voors, A. A., Pogoda, J. M., Provost, R., Guerrero, J., Hajjar, R. J., & Zsebo, K. M. (2016) · Gene Therapy · doi:10.1038/gt.2015.109 · Cited by 111
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117
“Intramuscular Administration: Experience in AAT-Deficiency Clinical Trials Brantly and colleagues reported the occurrence of cellular immune responses in a clinical trial for alpha-1-antitrypsin (AAT) deficiency, including IFN-gamma ELISPOT responses to AAV capsid, that did not completely eliminate transduced cells (3…”
BackgroundImmune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
Arruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
“In both trials, minor side effects and a seroconversion against AAV1 were observed (Brantly et al 2009; Flotte et al 2011).”
BackgroundHareendran, S., Balakrishnan, B., Sen, D., Kumar, S., Srivastava, A., & Jayandharan, G. R. (2013) · Reviews in Medical Virology · doi:10.1002/rmv.1762 · Cited by 113
“Similar responses have been noted in multiple other trials as well [14,15] including in patients treated with AAV1 vectors for LPL deficiency [16] and AAV2 vectors for DMD [9].”
Result5 Year expression and neutrophil defect repair after gene therapy in alpha-1 antitrypsin deficiency
Mueller, C., Gernoux, G., Gruntman, A. M., Borel, F., Reeves, E. P., Calcedo, R., Rouhani, F. N., Yachnis, A., Humphries, M., Campbell-Thompson, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.029 · Cited by 112
“The rAAV1-AAT vector has been used in a phase 1 trial of IM administration in AAT deficient adults and has demonstrated dose-dependent, sustained expression of M-AAT in the absence of significant adverse effects.(13,16,18,19)”
MethodSelf-citationCell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Basner-Tschakarjan, E., & Mingozzi, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00350 · Cited by 95
Monahan, P. E., Sun, J., Gui, T., Hu, G., Hannah, W. B., Wichlan, D. G., Wu, Z., Grieger, J. C., Li, C., Suwanmanee, T., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.106 · Cited by 108
“Additional histopathological examination included screening of livers for CD8 + T cells and evaluation of splenocytes for interferon-c enzymelinked immunospot (ELISPOT) immune response to AAV8 and FIXR338L protein.(25)”
MethodSalmon, F., Grosios, K., & Petry, H. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 93
The potential of adeno-associated viral vectors for gene delivery to muscle tissue
Wang, D., Zhong, L., Nahid, M. A., & Gao, G. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.871258 · Cited by 98
“Pig [159] Sheep [160] A1ATD [161], LGMD2D [162], LPLD [163] Heart failure [39]”
Understanding AAV vector immunogenicity: from particle to patient
Dhungel, B. P., Winburn, I. C., Pereira, C. D. F., Huang, K., Chhabra, A., & Rasko, J. E. J. (2024) · Theranostics · doi:10.7150/thno.89380 · Cited by 101
AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
M. Mitchell, A., C. Nicolson, S., K. Warischalk, J., & Jude Samulski, R. (2010) · Current Gene Therapy · doi:10.2174/156652310793180706 · Cited by 96
Herson, S., Hentati, F., Rigolet, A., Behin, A., Romero, N. B., Leturcq, F., Laforêt, P., Maisonobe, T., Amouri, R., Haddad, H., et al. (2012) · Brain · doi:10.1093/brain/awr342 · Cited by 91
“No serious adverse effects have so far been noted in the 200-plus patients who have received different AAV subtypes, at different doses, via different routes and in different indications (Manno et al., 2003, 2006; Kaplitt et al., 2007; Moss et al., 2007; Bainbridge et al., 2008; Cideciyan et al., 2008; Maguire et al.,…”
BackgroundBiosafety of Recombinant Adeno-associated Virus Vectors
Dismuke, D., Tenenbaum, L., & Samulski, R. (2014) · Current Gene Therapy · doi:10.2174/15665232113136660007 · Cited by 91
Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96
Adeno-associated virus-mediated cancer gene therapy: Current status
Luo, J., Luo, Y., Sun, J., Zhou, Y., Zhang, Y., & Yang, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.045 · Cited by 96
Ertl, H. C. J., & High, K. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.172 · Cited by 94
“80 Unlike in the hemophilia B trial, there was no relationship between vector dose and magnitude of the AAV capsid-specific T-cell response in the AAT trial.”
Chhabra, A., Bashirians, G., Petropoulos, C. J., Wrin, T., Paliwal, Y., Henstock, P. V., Somanathan, S., Pereira, C. D. F., Winburn, I. C., & Rasko, J. E. J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101273 · Cited by 92
α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment
Stockley, R. A., & Turner, A. M. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.11.006 · Cited by 92
Byrne, B. J., Falk, D. J., Pacak, C. A., Nayak, S., Herzog, R. W., Elder, M. E., Collins, S. W., Conlon, T. J., Clement, N., Cleaver, B. D., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr174 · Cited by 91
Self-citationVeron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84
Li, H., Lasaro, M. O., Jia, B., Lin, S. W., Haut, L. H., High, K. A., & Ertl, H. C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.81 · Cited by 83
Calcedo, R., Somanathan, S., Qin, Q., Betts, M. R., Rech, A. J., Vonderheide, R. H., Mueller, C., Flotte, T. R., & Wilson, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617726114 · Cited by 79
“TheAATpeptide librarywas divided into twopools,A andB, and theAAV virion peptide 1 (VP1) peptide library was divided into three pools, A, B, and C, as previously described (14).”
MethodSelf-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
“responses, although these seem to only account for a reduction of transgene expression, but not for vector elimination (72, 102, 103).”
BackgroundIn Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency
Song, C.-Q., Wang, D., Jiang, T., O'Connor, K., Tang, Q., Cai, L., Li, X., Weng, Z., Yin, H., Gao, G., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.225 · Cited by 75
“A transgenic mouse model for the study of AATD was generated in the 1980s and has been widely used for preclinical studies for gene therapy of AATDrelated disease.(10,11) A *14 kb human Z-AAT transgene was introduced into the germline of mice, resulting in a mouse strain (PiZ mice) that expresses artificially high lev…”
MethodSelf-citationMah, C. S., Falk, D. J., Germain, S. A., Kelley, J. S., Lewis, M. A., Cloutier, D. A., DeRuisseau, L. R., Conlon, T. J., Cresawn, K. O., Fraites Jr, T. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.305 · Cited by 77
Self-citationCalcedo, R., & Wilson, J. M. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.048 · Cited by 77
“17,18 To further understand the phenomenon of naturally occurring broadly cross-neutralizing NAb responses observed in nonhuman primates, we conducted a longitudinal study designed to analyze serum samples collected from captive housed chimpanzees over 10 years for AAV NAbs.”
Self-citationTherapeutic promise of engineered nonsense suppressor tRNAs
Porter, J. J., Heil, C. S., & Lueck, J. D. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1641 · Cited by 77
Jayandharan, G. R., Aslanidi, G., Martino, A. T., Jahn, S. C., Perrin, G. Q., Herzog, R. W., & Srivastava, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012753108 · Cited by 72
“These efforts include the use of alternate, naturally occurring AAV serotypes such as AAV1 (33) or AAV8 (34), the use of shuffled capsids (35) or surface-exposed tyrosine-mutant AAV2 (29) vectors, and the development of transient immune-suppression protocols (36, 37).”
BackgroundRetractedTseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70
“clinical trials, including the treatment of antitrypsin deficiency (10), lipoprotein lipase deficiency (11, 12), Pompe’s disease (ClinicalTrials.”
BackgroundMcIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70
SALIDO, E. C., Rodriguez-Pena, M., Santana, A., Beattie, S. G., Petry, H., & Torres, A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.270 · Cited by 70
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Haurigot, V., Mingozzi, F., Buchlis, G., Hui, D. J., Chen, Y., Basner-Tschakarjan, E., Arruda, V. R., Radu, A., Franck, H. G., Wright, J. F., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.73 · Cited by 66
Li, C., Xiao, P., Gray, S. J., Weinberg, M. S., & Samulski, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109522108 · Cited by 66
“AAV has also been used in two clinical trials in patients with AAT deficiency via muscular delivery (3, 4).”
MethodAssessment of Humoral, Innate, and T-Cell Immune Responses to Adeno-Associated Virus Vectors
Calcedo, R., Chichester, J. A., & Wilson, J. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.038 · Cited by 62
“More specifically, they may be use to evaluate (1) the humoral immune response, through levels of AAV-neutralizing and binding antibodies; (2) the innate immune response, through the acute induction of inflammatory cytokines; and (3) the T-cell immune response, through the activation of transgene- and vector-specific…”
InfluentialSelf-citationWu, T., Töpfer, K., Lin, S.-W., Li, H., Bian, A., Zhou, X. Y., High, K. A., & Ertl, H. C. (2012) · Molecular Therapy · doi:10.1038/mt.2011.280 · Cited by 66
Fuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Toromanoff, A., Adjali, O., Larcher, T., Hill, M., Guigand, L., Chenuaud, P., Deschamps, J.-Y., Gauthier, O., Blancho, G., Vanhove, B., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.251 · Cited by 61
Wang, Z., Tapscott, S. J., Chamberlain, J. S., & Storb, R. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00201 · Cited by 53
Human Galectin 3 Binding Protein Interacts with Recombinant Adeno-Associated Virus Type 6
Denard, J., Beley, C., Kotin, R., Lai-Kuen, R., Blot, S., Leh, H., Asokan, A., Samulski, R. J., Moullier, P., Voit, T., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00297-12 · Cited by 64
“rAAVs have proven to be efficient in preclinical studies in animal models (16, 28), and results from clinical trials are promising (7, 47).”
BackgroundProduction and Discovery of Novel Recombinant Adeno‐Associated Viral Vectors
Mueller, C., Ratner, D., Zhong, L., Esteves‐Sena, M., & Gao, G. (2012) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc14d01s26 · Cited by 56
Self-citationHigh, K. A., & Aubourg, P. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_18 · Cited by 60
Boisgerault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54
Chulay, J. D., Ye, G.-J., Thomas, D. L., Knop, D. R., Benson, J. M., Hutt, J. A., Wang, G., Humphries, M., & Flotte, T. R. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.118 · Cited by 60
“…method, the use of muscle injection for development of a clinical approach has several advantages, such as a more favorable profile of anti-capsid effector T-cell responses (Manno et al. , 2006; Brantly et al. , 2009) and a lower level of dissemination to distant sites (Manno et al. , 2003, 2006).”
Self-citationStrategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
“For instance, NAbs have been shown to exert minimal effects on transduction efficiency of intramuscularly administered AAV vectors in early clinical trials for a1-antitrypsin deficiency and hemophilia B [26-28].”
BackgroundNanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 61
Metadata
- Authors
- Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., Spencer, C., Byrne, B. J., Wilson, J. M., & Flotte, T. R.
- Affiliations
- University of Florida (US)
- Applied Genetic Technologies (United States) (US)
- University of Pennsylvania (US)
- University of Massachusetts Chan Medical School (US)
- Boston Children's Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-09-22
- Volume
- 106
- Issue
- 38
- Pages
- 16363-16368
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2752529
- OpenAlex
- W2083867423
- Cited by
- 327
- References
- 31
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 13 · 2020: 11 · 2019: 16 · 2018: 12 · 2017: 20 · 2016: 21 · 2015: 19 · 2014: 24 · 2013: 24 · 2012: 27
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- University of Florida
- Applied Genetic Technologies Corporation
- National Institutes of Health (and K24, DK047757)
- National Heart, Lung, and Blood Institute (R01HL69877, P01HL059412, R01HL069877, K24HL004456, K24 HL004456-5)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, P30DK047757, DK58327, DK047757-15)
- National Center for Research Resources (U42RR016586, M01RR000082)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- alpha-1 antitrypsin deficiency, T cell response, neutralizing antibodies, interferon-gamma, sustained transgene expression, dose escalation
- MeSH terms
- Dependovirus, Adult, Aged, alpha 1-Antitrypsin, Antibodies, Viral, Capsid, Cell Line, Enzyme-Linked Immunosorbent Assay, Female, Genetic Vectors, Humans, Injections, Intramuscular, Male, Middle Aged, Recombinant Fusion Proteins, T-Lymphocytes, Time Factors, Genetic Therapy, CD4-Positive T-Lymphocytes, Gene Expression, CD8-Positive T-Lymphocytes, alpha 1-Antitrypsin Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.